Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 221 - 230 of 243
Alternative Name: Tripterygium wilfordii derivatives, including triptolide
User: Male
Hormonal: No
Developer: WHO, University of California at Los Angeles
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: Testosterone undecanoate (TU) + etonogestrel (ENG)
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable, Subdermal
Developer: Organon
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Testosterone undecanoate (TU) + norethisterone enanthate (NET-EN)
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Bayer HealthCare, CONRAD, WHO
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: FHI 360, GE Healthcare
Development Stage: Prototype Development
Development Phase: Discovery and Early Development
Alternative Name: LNG Contraceptive IUS 12 (LCS12)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Bayer HealthCare
Development Stage: Regulatory
Development Phase: Limited Market Availability
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Population Council, Theramex, Rockefeller Foundation
Development Stage: Marketed
Development Phase: Limited Market Availability
Alternative Name: Ulipristal acetate (UPA) Intrauterine System (IUS)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: HRA Pharma, Population Council
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Ulipristal acetate (UPA) vaginal ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Population Council, HRA Pharma
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: S-003296
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Central Drug Research Institute, India
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Delivery Method: Vaginal, Other
Developer: University of Texas Health Science Center at San Antonio
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development

Pages

Displaying 31 - 40 of 70
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Development Stage: Compound ID/Selection
Alternative Name: Sperm glycolytic enzyme
Target
Hormonal: No
Developer: University of North Carolina at Chapel Hill, NICHD
Development Stage: Target Validation
Alternative Name: GES IUD
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR)
Development Stage: Prototype Development
Alternative Name: Gonadotropin releasing hormone II
Target
User: Female
Hormonal: Yes
Developer: CICRR, San Antonio, CONRAD
Development Stage: Target Identification
Alternative Name: Lactobacilli; LJ-102
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Developer: Hervana Bio
Development Stage: Lead Optimization
Alternative Name: HIFU
User: Male
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Vas Deferens
Developer: Vitality Medical Products
Development Stage: Prototype Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Injectable
Developer: Bayer HealthCare
Development Stage: Prototype Development
Alternative Name: LDH-C4, Lactate dehydrogenase C
Target
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Oral
Developer: Northwestern University
Development Stage: Target Identification
Alternative Name: Leukemia inhibitory factor (LIF) and interleukin-11 (IL-11)
Target
User: Female
Hormonal: No
Duration Type: Short-acting
Developer: Prince Henry's Institute of Medical Research, Australia
Development Stage: Target Validation
Alternative Name: (3β,13ξ)-Lup-20(29)-en-3-ol; Clerodol; Monogynol B; Fagarasterol; Farganasterol
User: Female, Male
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Oral, Other
Development Stage: Lead Optimization

Pages

Displaying 41 - 50 of 121
User: Male
Hormonal: No
Duration Type: Permanent, Short-acting
Delivery Method: Oral
Developer: WHO, South-to-South Cooperation in Reproductive Health
Development Stage: Phase I
Alternative Name: SARM C-6
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: GTx, Inc., Memphis, TN
Development Stage: Pre-clinical
Alternative Name: H2-GMZ
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Pre-clinical
Alternative Name: Injectable Gestodene (GES) + Ethinyl Estradiol (EE)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Peking University
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Stanford University
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: University of California San Diego
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: KYDES Pharmaceuticals, FHI 360
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: University of Tennessee Health Sciences Center
Development Stage: Pre-clinical
Alternative Name: Gendarussa
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Airlangga University, Indopharma, FHI 360
Development Stage: Phase II
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: ContraMed, LLC
Development Stage: Phase II

Pages

Displaying 51 - 52 of 52
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed

Pages

CSV